- Home
- ABBV vs GILD Comparison
ABBV vs GILD Comparison
Compare ABBV & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | GILD |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5B | 155.3B |
| IPO Year | 2012 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ABBV | GILD |
|---|---|---|
| Price | $247.71 | $125.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $253.71 | $148.39 |
| AVG Volume (30 Days) | 4.1M | ★ 7.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.39% | 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 0.39 | ★ 1.61 |
| Revenue | ★ $61,160,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $11.87 | $4.68 |
| Revenue Next Year | $8.12 | $6.04 |
| P/E Ratio | $625.28 | ★ $76.82 |
| Revenue Growth | 8.57 | ★ 9.98 |
| 52 Week Low | $181.75 | $107.75 |
| 52 Week High | $244.81 | $157.29 |
Technical Indicators
Market Signals| Indicator | ABBV | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 75.20 | 44.56 |
| Support Level | $213.65 | $116.55 |
| Resistance Level | N/A | $126.81 |
| Average True Range (ATR) | 5.90 | 3.53 |
| MACD | 2.32 | 0.17 |
| Stochastic Oscillator | 99.62 | 45.06 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).